MYX mayne pharma group limited

BOOK value $7.60 per share, page-19

  1. 1,060 Posts.
    lightbulb Created with Sketch. 86
    THIS CAN JUMP AT ANY TIME , ONCE THEY REPORT BACK EBITDA +VE , WHICH THEY ALREADY DID 2HFY2023 , 6 MONTH ONCE THEY REPORT ON 1HFY2024 , EVERYONE WILL REGRET SELLINING AND THEY CANT EVEN BUY BACK . COMPARING THSI TO OTHER ASX ;LISTED COMPANIES WHO HAVE EVEN 3 TIMES THE MARKET CAP AND COMPANIES THAT DOESN'T EVEN HAVE ANY REVENUE , MAYNE WOULD STAND , ALL WHAT THEY NEED IS COST REDUCTION WHICH IS ACHIEVABLE , ONCE THE RESTRUCTURE IMPACT IS FELT . THIS WILL GO BACK TO WHERE IT WAS 2016 . BEST STRATEGY . REMEBER THEY NOW MAKING MONEY ON TXMD PRODUCTS WITH HALF THE OPEX AND SELLING NEXTSTELLIS WITH NO COST AMONGST THOSE PRODUCTS , 70 M SAVINGS , AND THEY WORKING ON IMPROVING THE NET SELLING PRICE THROUGH DISINTERMEDIATION .
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$4.92
Change
-0.110(2.19%)
Mkt cap ! $399.7M
Open High Low Value Volume
$5.03 $5.03 $4.86 $1.730M 352.1K

Buyers (Bids)

No. Vol. Price($)
1 100 $4.88
 

Sellers (Offers)

Price($) Vol. No.
$4.93 25000 1
View Market Depth
Last trade - 16.15pm 23/06/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.